Latest news with #DDD
Qatar Tribune
3 days ago
- General
- Qatar Tribune
DDD and VCUarts Qatar collaborate tofoster sustainability through design
QNA Doha Doha Design District (DDD) and VCUarts Qatar have collaborated with artist Abdelrahman Al Muftah to design an innovative, sustainable sanctuary for Qatar's native Bulbul birds. The Bird Cluster project, which includes a planter, bird nest, watering tray and feeding tray, has been brought to life in Msheireb as part of DDD's commitment to advancing Qatar's Vision 2030, a future driven by sustainability and innovation. By encouraging collaboration and empowering emerging designers, this project exemplifies how DDD and VCUarts Qatar are cultivating local talent to create impactful solutions that benefit the community. Director of Doha Design District Dana Kazic said: 'This collaboration with VCUarts Qatar and Abdulrahman Al Muftah reflects our mission to nurture creativity and empower young designers to address real-world challenges through meaningful design. By merging sustainability with innovation, we're not only working towards contributing to our national vision but also inspiring the next generation of designers to think critically about their role in shaping a better future for our society.' Rab McClure, professor and director, MFA in Design, VCUarts Qatar, said: 'The Bird Cluster project embodies significant and meaningful ideas. It stands out for its research-driven design approach, supported through the collaborative efforts of VCUarts Qatar and Doha Design District. This work exemplifies the kind of locally rooted, socially conscious design we strive to cultivate, creating projects that help to advance the broader vision of a sustainable urban environment for all.' Al Muftah worked closely with DDD and VCUarts Qatar to ensure the structure was both sustainable and innovative. Inspired by traditional Qatari architecture, the design seamlessly integrates into the urban landscape while providing functional nesting spaces for smaller birds. The compact yet secure structure features entry points specifically designed to exclude larger invasive species, ensuring a haven for Qatar's native Bulbul birds. This attention to detail highlights the project's dual focus on preserving biodiversity and maintaining harmony with the environment. Abdulrahman Al Muftah, designer of The Bird Cluster, expressed: 'Working with Doha Design District and VCUarts Qatar's Boost Lab to bring this project to life was truly rewarding. As a designer, I'm passionate about integrating flora and fauna into public spaces because it creates environments that support biodiversity and multiple species can thrive together. For me, thoughtful design goes beyond aesthetics - it's about understanding and considering the broader environmental impact of what we create. Every design decision ripples outward, affecting not just human users but entire ecosystems.' This initiative emphasises the broader significance of collaborative efforts between DDD and VCUarts Qatar. By bringing together creative minds, local expertise, and forward-thinking design principles, projects like this contribute meaningfully to society, benefiting both the environment and the community. Through this partnership, DDD and VCUarts Qatar continue to demonstrate how design can be a powerful tool for driving positive change and building a more sustainable future for Qatar.
Qatar Tribune
5 days ago
- Entertainment
- Qatar Tribune
Msheireb Museums' Summer Programme advances cultural education
Tribune News Network Doha Msheireb Museums' 2025 Summer Programme has successfully engaged young cultural ambassadors throughout July, further establishing its reputation as Qatar's leading heritage education destination whilst building anticipation for August's expanded programming. The programme's initial success stems to Msheireb Museums' distinctive approach to cultural preservation – moving beyond traditional display methods to create immersive, participatory experiences that connect the country's heritage with contemporary creative expression. July achievements through strategic collaboration The partnership between Virginia Commonwealth University School of the Arts Qatar (VCUarts Qatar) and Doha Design District (DDD) delivered outstanding cultural learning experiences: Interior Design: Past Meets Present enabled participants to examine Radwani House's traditional architectural principles whilst developing contemporary design solutions that honour cultural authenticity. Creative Msheireb Patterns engaged participants in exploring Msheireb's distinctive architectural vocabulary through design-focused art techniques and the Arabic Calligraphy workshops preserved classical Dewani script traditions through heritage-inspired narrative creation. Moreover, CamelCode's innovative technology integration proved particularly successful, with Reviving the Past Through Robotics demonstrating how contemporary tools can enhance historical understanding. The Memory-Inspired Game Design sessions encouraged participants to recreate family and community narratives into interactive digital experiences, offering a contemporary way to engage with heritage through Artificial Intelligence (AI) and digital media. August programming: connecting heritage with creativity Building upon July's achievements, the August programming continues to showcase a range of workshops led by VCUarts Qatar, in collaboration with DDD, inviting participants to connect with Qatar's cultural heritage through both traditional craftsmanship and modern artistic techniques. The sessions include digital art inspired by Qatari architecture, clay and storytelling activities designed for younger participants, and visual storytelling using collage and illustration based on Msheireb's cultural themes. Alongside these, CamelCode continues to offer its technology-focused workshops, enabling participants to engage with heritage through robotics, memory-inspired game design, and immersive virtual experiences. This month features the comprehensive Inclusive Discovery Outing Camp by Life Skills Hub, running from 3 to 28 August at Msheireb Museums This pioneering programme ensures cultural accessibility for children and young adults with diverse learning requirements through specially designed activities, educational outings, and sensory experiences. 'The success of this summer programme demonstrates how strategic partnerships can transform heritage education. By combining DDD's design expertise with Msheireb's cultural vision and the excellence of various stakeholders, we're creating meaningful pathways for young people to engage with Qatar's rich architectural heritage while developing contemporary creative skills,' noted Dana Kazic, director of Doha Design District. 'This collaboration with Msheireb Museums and Doha Design District reflects a shared commitment to strategic, impact-driven partnerships that advance arts and design education through cultivating a thriving creative ecosystem rooted in innovation, contemporary practice and cultural heritage. 'The Community Education programme at VCUarts Qatar aims to expand access to meaningful, hands-on learning experiences that empower participants of all ages to engage with art and design in ways that are relevant, inclusive, and future-focused, and this collaborative summer programme was perfectly aligned with this mission,' added Lejla Niksic, director of Strategic Engagement at VCUarts programming focuses on heritage innovation
Business Wire
01-08-2025
- Business
- Business Wire
Spine BioPharma Announces Topline Results from Phase 3 MODEL Trial For SB-01
NEW YORK--(BUSINESS WIRE)--Spine BioPharma, Inc. announced today the Phase 3 MODEL trial (MO derate – Severe Degenerative D isc Disease E valuation of the L umbar Spine) evaluating SB-01, a TGF-β antagonist for intradiscal treatment of patients with Chronic Low Back Pain (CLBP) associated with Degenerative Disc Disease (DDD), did not meet its primary endpoint of pain intensity and pain-related function at Month 6 post treatment compared to sham control. A single intradiscal injection of SB-01 in CLBP patients associated with DDD demonstrated: A robust safety profile consistent with the previous Phase 2 study. SB-01 patients saw a numerical and clinically meaningful improvement in pain intensity and pain-related function. The SB-01 response was observed at all timepoints out to Month 6 and was durable at one year. There was no difference in success at any timepoint between 1- and 2-level patients. There was an inconsistent sham control response among sites, with some sites having much higher than anticipated sham control rates. In sites with an anticipated sham control response, SB-01 outperformed the sham control, almost achieving nominal statistical significance p=0.051. The clinical trial was prospective, 1:1 randomized with 417 patients utilizing a single 1.5 ml intradiscal injection of SB-01 or a sham control. Both 1- and 2-level DDD patients were enrolled across 30 sites in the United States. Patients were followed at Week 2, Week 6, Month 3 and to the primary endpoint at Month 6 with an additional follow-up at Month 12. Patients were evaluated for pain intensity utilizing Numerical Rating Scale (NRS) and pain-related function using Oswestry Disability Index (ODI). Patients had to achieve both a 2/10-point improvement in NRS and 15/100-point improvement in ODI to be considered an overall composite success (primary endpoint). As previously observed in the Phase 2 clinical trial of 325 patients, and in this Phase 3 clinical trial of 417 patients, SB-01 demonstrated a robust safety profile. In the Intent-to-Treat (ITT) analysis of the 417 patients, the SB-01 group achieved primary endpoint success (ODI+NRS) of 67% at Month 6, which although clinically meaningful, did not reach statistical significance compared to the sham control group. The SB-01 response was present at the early timepoints. For the patients that reached the Month 12 follow-up at database lock (N=281), 62% of the SB-01 group achieved composite success (ODI+NRS). There was no difference in SB-01 success at any timepoint between 1- and 2-level patients. In a secondary endpoint ITT analysis of pain-related function (ODI), the SB-01 group achieved a clinically meaningful success rate of 75% at Month 6, and 71% at Month 12 but was not statistically significant compared to the sham control. Fran Magee, DVM, CTO, stated 'The SB-01 patients responded as anticipated and consistent with the Phase 2 study. In contrast, the sham control response was statistically significantly higher than observed in the Phase 2 study. The statistical design of this Phase 3 study anticipated a high sham control success, as observed in the Phase 2 study and typically seen in CLBP studies. We are surprised by the very high sham control response in this study that kept us from achieving statistical significance.' In this Phase 3 study, the very high sham response was not observed at all investigational sites. There is statistically reliable evidence of site-to-site heterogeneity in the sham control response with some sites demonstrating exceedingly high sham control response that was not observed in the homogenous SB-01 response across sites. Given the site-to-site sham control response variability, a subset analyzing only patients (n=227) at sites that had an anticipated sham response, consistent with the previous Phase 2 study was performed. For the ITT analysis, utilizing the composite primary endpoint (ODI+NRS) the response in the SB-01 and sham control group was 70% and 59% respectively, nominal p=0.051. In the same patient subset, the secondary endpoint of ODI response in the SB-01 and sham control group was 79% and 69% respectively and compared to sham control with a nominal p=0.040. These analyses demonstrate that in the sites that had the anticipated sham control response rate, SB-01 outperformed the sham control patients. Marc Viscogliosi, CEO, stated 'Despite our disappointment in missing the primary endpoint, we are quite proud of enrolling and completing this trial under strict FDA guidelines. We ran a solid trial and had we achieved our anticipated sham control group response, the results would have been statistically significant in favor of SB-01.' Christopher Gilligan, MD, Principal Investigator of the MODEL trial stated 'This was a landmark, well-designed clinical trial with strict enrollment criteria and very high follow-up rates. The study employed a rigorous composite endpoint requiring patients to achieve both clinically meaningful improvement in both pain intensity and pain-related function. Pain studies are challenging and are susceptible to a sham control response, which was particularly high in this study. We are thankful to the patients, their families, investigators, clinical coordinators, and research associates who participated in this clinical trial for CLBP.' There remains a significant need for less invasive, safe and effective treatment for CLBP associated with DDD. Spine BioPharma will complete the data analysis. We plan to meet with the FDA to discuss the results from this Phase 3 trial together with the earlier Phase 1 and 2 randomized trials and explore potential approval pathways for SB-01 as a treatment for CLBP associated with moderate-severe DDD. About the MODEL Clinical Trial SB-01 MODEL clinical trial is a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 trial being conducted to establish the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and its associated impairment in pain-related function due to Lumbar DDD. About SB-01 For Injection SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. TGF-Beta is a pleiotropic cytokine expressed by almost every tissue and cell type, is stored in abundance in the extracellular matrix, and possesses suppressive and stimulatory signaling pathways. In many diseases, there are high concentrations of TGF-Beta that result in a spectrum of negative downstream effects including inflammation, fibrosis, neoinnervation, hyperexcitability of nerves and cell proliferation. SB-01 modulates TGF-Beta concentration, without eliminating it, mitigating the negative downstream effects. About Spine BioPharma Spine BioPharma is committed to developing non-opiate, non-surgical treatments that will reduce pain, restore function, and slow or stop pathological disease progression. Spine BioPharma's lead candidate, SB-01 For Injection, is a first-in-class treatment of DDD, offering potential clinical benefits of pain relief, restoration of function, and prevention of disease progression. To learn more about Spine BioPharma, visit
Scottish Sun
17-07-2025
- Sport
- Scottish Sun
Oleksandr Usyk hilariously faces off with 73-year-old promoter Frank Warren after tense Daniel Dubois stare-down
All recommendations within this article are informed by expert editorial opinion. If you click on a link in this story we may earn affiliate revenue. DDD also hit back at criticism from Usyk's camp FACING THE USYK Oleksandr Usyk hilariously faces off with 73-year-old promoter Frank Warren after tense Daniel Dubois stare-down Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FRANK WARREN had to fill in and face-off with Oleksandr Usyk after Daniel Dubois walked off the stage following a tense stare-down. The 73-year-old Hall of Fame promoter is backing his man Dubois to avenge his 2023 loss and hand Usyk a first professional defeat. Sign up for Scottish Sun newsletter Sign up 4 Oleksandr Usyk faces off with promoter Frank Warren Credit: PA And Warren got up close and personal with the two-weight undisputed champion on the press conference stage. The legendary Queensberry Promotions chief went nose-to-nose with the often comedic Usyk for a hilarious face-off. But while it was all smiles between the two camps - just moments beforehand Usyk and Dubois locked eyes just two days out from their rematch. The Ukrainian, 38, WBC, WBA and WBO unified champion stopped Dubois, 27, in nine rounds when they first met. READ MORE IN BOXING GETTING THE DUB Daniel Dubois must be a 'crazy DEMON' to beat Oleksandr Usyk, warns Chisora But it followed after he was floored by a low-blow that Dubois has always argued was legal. The Londoner has since bounced back with wins over Jarrell Miller and Filip Hrgovic - before knocking out Anthony Joshua in September. Now the IBF champ, he said: "I've prepared right. I'm on a different level now. "I'm ready to go through what I need to Saturday to get those belts. I'm chasing glory and I'm chasing greatness." 4 USYK VS DUBOIS 2: Stream, TV channel and undercard info for blockbuster Wembley fight Watch Usyk vs Dubois 2 LIVE on DAZN CASINO SPECIAL - BEST CASINO BONUSES FROM £10 DEPOSITS Dubois' heart has come into question by Usyk's camp following his loss in Poland two years ago. And amid the low-blow controversy - the bad blood has been brewing ahead of the rematch for all four belts. But Dubois said the allure of revenge and undisputed glory motivates him in equal measure. He said: "All of it. The whole thing. This is history making and I've just got to do a real demolition job. I'm hungry, I'm ready for it." 4 Usyk won in the ninth round in 2023 Credit: Richard Pelham / The Sun
Associated Press
06-07-2025
- Business
- Associated Press
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of 3D Systems
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In 3D Systems To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in 3D System between August 13, 2024 and May 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against 3D Systems Corporation ('3D Systems' or the 'Company') (NYSE: DDD) and reminds investors of the August 12, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) 3D Systems had understated the impact of weakened customer spending on the Company's business, while overstating its resilience in challenging industry conditions; (2) in addition, the updated milestone criteria in the United Partnership would negatively impact the Company's Regenerative Medicine Program revenue; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times. On March 26, 2025, 3D Systems issued a press release announcing its financial results for the fourth quarter ('Q4") and full-year 2024. Among other items, 3D Systems reported Q4 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08 per share, and sales revenue of $111 million, representing a -3.4% year-over-year decline and missing consensus estimates by $4.17 million. Further, for full-year 2024, the Company reported sales of $440.1 million, a decrease of 10% compared to the prior year, driven by 'lower hardware systems sales due to macroeconomic factors that are negatively impacting demand.' Finally, 3D systems reported a "$9 million revenue reduction in Q4 driven by a change in accounting estimates for [the Company's] Regenerative Medicine program.' The Company disclosed that "[t]his change in estimate [was] related to the now anticipated use of pre-clinical human decedent testing[,] [. . .] which led to refinement of the milestone technical criteria.' On this news, 3D Systems' stock price fell $0.57 per share, or 20.96%, to close at $2.15 per share on March 27, 2025. Then, after the market closed on May 12, 2025, 3D Systems issued a press release announcing its financial results for the first quarter ('Q1") of 2025. Among other items, 3D systems reported: revenue of $94.5 million, down 8% year-over-year and missing consensus estimates of $99.5 million; a net loss of $37 million, or $0.28 per share, more than doubling the $16 million loss reported in Q1 2024; an adjusted loss of $0.21 per share, deeper than consensus estimates of a loss of $0.14 per share; and adjusted EBITDA of a loss of $23.9 million, deepening from a $20.1 million loss in Q1 2024. The Company attributed its disappointing results, in part, to a decline in material sales, mostly due to inventory management issues in the dental portion of its Healthcare Solutions segment. 3D Systems also announced that it was withdrawing its full-year 2025 outlook, citing prolonged softness in customer capital spending and macroeconomic uncertainty. On this news, 3D Systems' stock price fell $0.68 per share, or 26.6%, to close at $1.87 per share on May 13, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding 3D Systems' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the 3D Systems class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at
